nd AVA-201 in wet age-related macular degeneration (wet AMD). • "Investors need a clear path forward=94 before getting back in AAVL, Cowen analyst Phil Na=eau writes in note; sees upside for shrs if AAVL gene t=erapies progress * PT cut to $25 vs $55, remain= outperform • "AVA-101 back to drawing boa